Global Visceral Pain Market – Industry Trends and Forecast to 2030

Visceral Pain Market Analysis and Size

The global visceral pain market is expected to witness significant growth during the forecast period. The governments of numerous countries and pharmaceutical companies are progressively investing in research & development to develop novel drugs, which is projected to boost the global visceral pain treatment market growth during the forecast period. The market is expected to grow considerably during the forecast period due to better collaboration among pharmaceutical companies.

Data Bridge Market Research analyzes that the visceral pain market which was USD 12.97 billion in 2022, would reach up to USD 20.21 billion by 2030, and is expected to undergo a CAGR of 5.70% during the forecast period. “Nonsteroidal Anti-Inflammatory (NSAID)” dominates the drug class segment of the visceral pain market due to beneficial therapeutic effect offered by these drugs for pain management. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Visceral pain is generalized internal pain characterized by constant, sharp and squeezing aching of the body. It is usually caused by medical conditions such as trauma, infection and chronic disease which results in inflammation abdominal region including stomach, uterus, bladder and rectum. Visceral pain mainly occurs because of activation of nociceptors of the thoracic, pelvic, or abdominal viscera. Several bodily injuries, including gallbladder, intestines, bladder, or kidneys, could cause visceral pain. Symptomatic treatment depends on medications such as painkillers, spasmolytics, and antidepressants. 

Visceral Pain Market Dynamics

Drivers

• Growing prevalence of visceral pain conditions

The growing prevalence of visceral pain conditions serves as a primary driver for the visceral pain treatment market. Increased awareness, improved diagnostic techniques, and evolving healthcare practices contribute to a better understanding of disorders causing visceral pain, such as gastrointestinal and urogenital conditions. As these conditions are identified more accurately, there is a rising demand for targeted and effective treatments. This trend is further amplified by the aging population and lifestyle factors, leading to an uptick in individuals seeking medical attention for visceral pain symptoms. The expanding patient pool underscores the need for innovative pharmaceuticals and medical interventions, fuelling research and development efforts within the healthcare industry.

• Rising demand for analgesics

It has been witnessed that the first-line treatment of visceral pain is using non-opioid analgesics. Some over-the-counter non-steroidal anti-inflammatories (NSAIDs) category analgesic, which are mainly used in visceral pain treatment include Aleve (naproxen) and aspirin (acetylsalicylic acid). In August 2020, Lannett Company, Inc. declared the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, an opioid pain reliever, under the companies' newly announced interim exclusive supply and distribution agreement. Thus, this analgesics are creating much awareness about the market and is boosting the growth of the market.

Opportunities

• Drug development and pharmaceuticals

As understanding of visceral pain mechanisms improves, there will be a growing demand for pharmaceuticals that target specific pathways involved in visceral pain. Companies have the opportunity to develop novel pain management drugs with improved efficacy and fewer side effects. Also, Tailoring drugs to individual patients based on their genetic makeup and other factors could become a significant area of development.

• Digital health solutions

The growth in visceral pain management may lead to increased adoption of telemedicine and digital health solutions for remote patient monitoring and support. Opportunities may arise for the development of mobile applications that help individuals track and manage visceral pain symptoms.

Restraints/Challenges

• Risk of opioid dependence

The use of opioids for visceral pain management poses a significant challenge due to the inherent risk of dependence and addiction. Prolonged opioid use can lead to tolerance, requiring higher doses for the same pain relief, thereby increasing the potential for adverse effects. Striking a balance between providing effective pain relief and minimizing the risk of opioid-related issues is a complex task, necessitating the exploration of alternative analgesic approaches.

• Side effects of current therapies

Existing treatments for visceral pain, including medications, often come with a range of side effects that can impact patient adherence and overall well-being. Balancing the relief of visceral pain with the potential adverse effects of medications poses a clinical challenge. Clinicians must carefully weigh the benefits of pain management against the impact of side effects on a patient's quality of life, emphasizing the need for personalized and targeted therapeutic interventions.

This visceral pain market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the visceral pain market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2019, Ironwood Pharmaceuticals Inc. declared the approval of ‘LINZESS’ with a strength of 72 mcg, 145 mcg, and 290 mcg in China for the treatment of irritable bowel syndrome (IBS) along with constipation in adults

Global Visceral Pain Market Scope

The visceral pain market is segmented on the basis of drug class, indications, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Calcium Channel Blockers
• Nonsteroidal Anti-Inflammatory (NSAID)
• Others

Indications

• Interstitial Cystitis
• Crohn’s
• Irritable Bowel
• Chronic Prostatitis
• Others

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Visceral Pain Market Regional Analysis/Insights

The visceral pain market is analysed and market size insights and trends are provided by country, drug class, indications, end users and distribution channel as referenced above.

The countries covered in the visceral pain market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

North America is expected to dominate the market due to large number of patients diagnosed with heart diseases and high R&D and healthcare expenditure.

Asia-Pacific is expected to witness the highest growth for global visceral pain market in the forecasted period due to rising cardiac surgeries & the continuous rise in patients with cardiovascular diseases and rapidly improving health care infrastructure in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The visceral pain market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for visceral pain market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the visceral pain market. The data is available for historic period 2010-2020.

Competitive Landscape and Visceral Pain Market Share Analysis

The visceral pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to visceral pain market.

Some of the major players operating in the visceral pain market are:

• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• AbbVie Inc.(Ireland)
• Dr. Reddy's Laboratories Ltd (India)
• Endo International plc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Sun Pharmaceutical Industries Ltd (India)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Lupin (India)
• Cipla Inc (India)
• Aurobindo Pharma (India)

SKU-54276